Ayyub Ghori Masood, Bakir Sherif, Ellahham Samer, Al Nassir Adnan, Al Zubaidi Abdulmajeed, Augustin Norbert, Abdelaziz Moataz Ayman, Turrin Nicolas Patrick, Al Mahmeed Wael Abdulrahman
Cardiac Science Department, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
J Saudi Heart Assoc. 2011 Apr;23(2):93-5. doi: 10.1016/j.jsha.2010.09.004. Epub 2010 Oct 15.
In the few reported cases of prosthetic mitral valve thrombosis, where surgical intervention was considered as high risk, fibrinolytic therapy had proved life saving. The authors present clinical, laboratory, and imaging data from such a patient, with prosthetic mitral valve thrombosis and its successful management with tenecteplase. The use of tenecteplase as a viable fibrinolytic agent for the first time was justified, due to the lack of immunogenicity concerns compared to streptokinase.
在少数已报道的人工二尖瓣血栓形成病例中，手术干预被认为风险很高，而纤维蛋白溶解疗法已被证明可挽救生命。作者展示了一名此类患者的临床、实验室和影像学数据，该患者患有人工二尖瓣血栓形成，并通过替奈普酶成功治疗。由于与链激酶相比不存在免疫原性问题，首次将替奈普酶用作一种可行的纤维蛋白溶解剂是合理的。
